Deerfield Management Company, L.P.
New York, NY
$8.0bn in 72 US stocks at the end of 30 June 2026. The top 10 are 57.1% of the money. It changed about 15.1% of the portfolio this quarter.
Value
$8.0bn
Stocks
72
Top 10 share
57.1%
Turnover
15.1%
What changed this quarter
New
Bought for the first time this quarter.
- Mineralys TherapeuticsMLYS1.3% of the fund
- Boston ScientificBSX0.7% of the fund
- Parabilis MedicinesPBLS0.6% of the fund
- Avalyn PharmaAVLN0.3% of the fund
- Odyssey TherapeuticsODTX0.2% of the fund
- Alamar BiosciencesALMR0.2% of the fund
- ChemedCHE0.2% of the fund
- AdageneADAG0.1% of the fund
- Hemab Therapeutics HoldingsCOAG0.1% of the fund
- Mobia MedicalMOBI0.1% of the fund
- Mirum PharmaceuticalsMIRM<0.1% of the fund
Added
Bought more of a stock they already held.
- Revolution MedicinesRVMD5.6% of the fund+4%
- Legend BiotechLEGN2.9% of the fund+6%
- Genmab A/SGMAB2.3% of the fund+179%
- Vera TherapeuticsVERA2.1% of the fund+5%
- PharvarisPHVS1.5% of the fund+8%
- Dianthus TherapeuticsDNTH1.4% of the fund+10%
- IDEAYA BiosciencesIDYA1.3% of the fund+77%
- Biomarin PharmaceuticalBMRN0.9% of the fund+57%
- Structure TherapeuticsGPCR0.7% of the fund+41%
- Belite BIOBLTE0.7% of the fund+17%
- Tyra BiosciencesTYRA0.4% of the fund+85%
Cut
Sold some of their stake.
- CenteneCNC3.9% of the fund-17%
- Cogent BiosciencesCOGT2.4% of the fund-45%
- CelcuityCELC1.9% of the fund-15%
- Arrowhead PharmaceuticalsARWR1.4% of the fund-12%
- Lantheus HoldingsLNTH1.0% of the fund-9%
- Indivior PharmaceuticalsINDV0.8% of the fund-47%
- Inspire Medical SystemsINSP0.7% of the fund-52%
- CareDxCDNA0.7% of the fund-9%
- CertaraCERT0.6% of the fund-4%
- Sionna TherapeuticsSION0.4% of the fund-30%
- VeracyteVCYT<0.1% of the fund-86%
Sold out
Sold their entire stake.
- Catalyst Pharmaceuticals-100%
- Neurocrine BiosciencesNBIX-100%
- DAY One Biopharmaceuticals I-100%
- Enhabit-100%
- Kymera TherapeuticsKYMR-100%
- Compass TherapeuticsCMPX-100%
- Taysha Gene TherapiesTSHA-100%
- Cullinan TherapeuticsCGEM-100%
- Biomx-100%
- VeradermicsMANE-100%
- Quantum SI-100%
- Myriad GeneticsMYGN-100%
Holdings
- Nuvalent
- Share
- 26.5%
- Value
- $2.1bn
- Shares
- 17,248,450
Held
- Legend BiotechLEGN
- Share
- 2.9%
- Value
- $235m
- Shares
- 8,137,638
+6%
- Genmab A/SGMAB
- Share
- 2.3%
- Value
- $189m
- Shares
- 6,865,000
+179%
- Structure TherapeuticsGPCR
- Share
- 0.7%
- Value
- $58m
- Shares
- 1,086,000
+41%
- Belite BIOBLTE
- Share
- 0.7%
- Value
- $55m
- Shares
- 357,199
+17%
- Parabilis MedicinesPBLS
- Share
- 0.6%
- Value
- $51m
- Shares
- 1,880,704
New
- Avalyn PharmaAVLN
- Share
- 0.3%
- Value
- $24m
- Shares
- 731,000
New
- Bright Minds BiosciencesDRUG
- Share
- 0.2%
- Value
- $20m
- Shares
- 283,000
Held
- Odyssey TherapeuticsODTX
- Share
- 0.2%
- Value
- $20m
- Shares
- 1,046,139
New
- Alamar BiosciencesALMR
- Share
- 0.2%
- Value
- $16m
- Shares
- 600,000
New
- Hemab Therapeutics HoldingsCOAG
- Share
- 0.1%
- Value
- $10m
- Shares
- 275,000
New
- Mobia MedicalMOBI
- Share
- 0.1%
- Value
- $9m
- Shares
- 670,752
New
- Newamsterdam Pharma CompanyNAMSW
- Share
- <0.1%
- Value
- $2m
- Shares
- 92,787
Held
- the Oncology InstituteSTLNW
- Share
- <0.1%
- Value
- $51,000
- Shares
- 1,250,000
Held
- Surrozen
- Share
- <0.1%
- Value
- $2,750
- Shares
- 166,666
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Nuvalent | 26.5% | $2.1bn | 17,248,450 | Held |
| Revolution MedicinesRVMD | 5.6% | $448m | 2,392,000 | +4% |
| Praxis Precision MedicinesPRAX | 4.0% | $323m | 963,351 | Held |
| ViatrisVTRS | 4.0% | $321m | 20,206,170 | Held |
| CenteneCNC | 3.9% | $315m | 4,901,000 | -17% |
| United TherapeuticsUTHR | 3.1% | $248m | 457,000 | Held |
| Legend BiotechLEGN | 2.9% | $235m | 8,137,638 | +6% |
| Cogent BiosciencesCOGT | 2.4% | $194m | 5,006,104 | -45% |
| Genmab A/SGMAB | 2.3% | $189m | 6,865,000 | +179% |
| Brookdale Senior LivingBKD | 2.3% | $187m | 11,637,032 | Held |
| Vera TherapeuticsVERA | 2.1% | $168m | 3,916,400 | +5% |
| Ionis PharmaceuticalsIONS | 2.0% | $157m | 1,979,669 | Held |
| CelcuityCELC | 1.9% | $152m | 1,451,014 | -15% |
| Biocryst PharmaceuticalsBCRX | 1.9% | $151m | 15,096,403 | Held |
| NewAmsterdam PharmaNAMS | 1.8% | $145m | 4,264,789 | Held |
| Acadia Healthcare CompanyACHC | 1.7% | $133m | 4,520,000 | Held |
| Tango TherapeuticsTNGX | 1.6% | $131m | 4,190,611 | Held |
| AdaptHealthAHCO | 1.5% | $120m | 11,477,730 | Held |
| PharvarisPHVS | 1.5% | $117m | 3,376,042 | +8% |
| Arrowhead PharmaceuticalsARWR | 1.4% | $113m | 1,389,055 | -12% |
| Dianthus TherapeuticsDNTH | 1.4% | $110m | 1,125,313 | +10% |
| Larimar TherapeuticsLRMR | 1.4% | $109m | 35,606,974 | Held |
| Mineralys TherapeuticsMLYS | 1.3% | $107m | 3,958,000 | New |
| IDEAYA BiosciencesIDYA | 1.3% | $101m | 2,714,503 | +77% |
| Xenon PharmaceuticalsXENE | 1.2% | $98m | 1,615,696 | Held |
| SavaraSVRA | 1.0% | $84m | 13,569,000 | Held |
| Lantheus HoldingsLNTH | 1.0% | $84m | 752,999 | -9% |
| Syndax PharmaceuticalsSNDX | 1.0% | $83m | 3,779,900 | Held |
| Biomarin PharmaceuticalBMRN | 0.9% | $76m | 1,332,836 | +57% |
| PfizerPFE | 0.9% | $73m | 3,040,000 | Held |
| Indivior PharmaceuticalsINDV | 0.8% | $68m | 1,648,895 | -47% |
| Bio-Rad LaboratoriesBIO | 0.8% | $66m | 226,070 | Held |
| ARS PharmaceuticalsSPRY | 0.7% | $60m | 7,503,812 | Held |
| Stoke TherapeuticsSTOK | 0.7% | $60m | 1,823,500 | Held |
| Structure TherapeuticsGPCR | 0.7% | $58m | 1,086,000 | +41% |
| Envista HoldingsNVST | 0.7% | $58m | 2,210,100 | Held |
| Inspire Medical SystemsINSP | 0.7% | $58m | 1,296,862 | -52% |
| CareDxCDNA | 0.7% | $57m | 1,997,618 | -9% |
| Boston ScientificBSX | 0.7% | $56m | 1,315,000 | New |
| Belite BIOBLTE | 0.7% | $55m | 357,199 | +17% |
| Parabilis MedicinesPBLS | 0.6% | $51m | 1,880,704 | New |
| CertaraCERT | 0.6% | $49m | 7,512,928 | -4% |
| Disc MedicineIRON | 0.6% | $48m | 657,000 | Held |
| BridgeBio Oncology TherapeuticsBBOT | 0.5% | $37m | 4,885,446 | Held |
| Tyra BiosciencesTYRA | 0.4% | $32m | 1,017,000 | +85% |
| Monopar TherapeuticsMNPR | 0.4% | $30m | 323,745 | Held |
| Sionna TherapeuticsSION | 0.4% | $30m | 680,916 | -30% |
| Avalyn PharmaAVLN | 0.3% | $24m | 731,000 | New |
| Foghorn TherapeuticsFHTX | 0.3% | $21m | 4,394,367 | Held |
| Beta BionicsBBNX | 0.3% | $21m | 1,324,000 | Held |
| Alnylam PharmaceuticalsALNY | 0.3% | $20m | 67,935 | Held |
| Bright Minds BiosciencesDRUG | 0.2% | $20m | 283,000 | Held |
| Odyssey TherapeuticsODTX | 0.2% | $20m | 1,046,139 | New |
| Starling OncologySTLN | 0.2% | $18m | 3,360,052 | Held |
| Kyverna TherapeuticsKYTX | 0.2% | $18m | 2,000,000 | Held |
| Alamar BiosciencesALMR | 0.2% | $16m | 600,000 | New |
| ChemedCHE | 0.2% | $14m | 30,000 | New |
| SpyGlass PharmaSGP | 0.2% | $12m | 550,000 | Held |
| AdageneADAG | 0.1% | $11m | 2,666,666 | New |
| Hemab Therapeutics HoldingsCOAG | 0.1% | $10m | 275,000 | New |
| Mobia MedicalMOBI | 0.1% | $9m | 670,752 | New |
| EmbectaEMBC | 0.1% | $8m | 2,534,961 | Held |
| VeracyteVCYT | <0.1% | $6m | 101,000 | -86% |
| AnnexonANNX | <0.1% | $3m | 583,913 | Held |
| AlectorALEC | <0.1% | $2m | 1,055,192 | Held |
| Newamsterdam Pharma CompanyNAMSW | <0.1% | $2m | 92,787 | Held |
| Edwards LifesciencesEW | <0.1% | $1m | 13,702 | Held |
| Mirum PharmaceuticalsMIRM | <0.1% | $705,581 | 6,027 | New |
| HumanaHUM | <0.1% | $364,251 | 917 | Held |
| the Oncology InstituteSTLNW | <0.1% | $51,000 | 1,250,000 | Held |
| PMV PharmaceuticalsPMVP | <0.1% | $11,779 | 8,790 | Held |
| Surrozen | <0.1% | $2,750 | 166,666 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 62.9% since 30 June 2025.
Where the money is
Health care66.2%
Technology0.6%
Other33.2%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.